“Mentice’s solutions will become even more crucial in the future”, says...
Mentice has announced the appointment of Frans Venker as its new CEO, effective January 1, 2025. He brings over 25 years of industry experience,...
“We show increasing sales but there is still a lot of...
PHI specializes in non-invasive cell analysis, enabling researchers to study cells without disrupting their natural state. The company’s products and technology are utilized by...
Medivir’s phase Ib/IIa study successfully concluded
Medivir has announced the conclusion of its phase Ib/IIa study evaluating fostrox in combination with Lenvima for second- or third-line treatment of advanced liver...
Saniona’s CEO: “The deal with Acadia is significant”
Saniona has announced a partnership with Acadia Pharmaceuticals to develop and commercialize SAN711. The total potential deal size is USD 610 million, including an...
New and larger shareholders back SynAct’s capital raise – CEO comments
SynAct Pharma has announced a capital raise of approximately SEK 65 million. The funding, subject to approval by an extraordinary general meeting, will be...
Another successful summit – watch all videos here
On November 20–21, we hosted the seventh annual BioStock Life Science Summit, and now you can watch the full program online! Over 30 companies...
BioStock Life Science Summit 2024 kicks off today
Today marks the start of the seventh annual BioStock Life Science Summit, a two-day event where over 30 life science companies will present their...
Lipum presents promising phase I data at ACR 2024
Lipum will present positive data from the phase I study of its drug candidate SOL-116 at the American College of Rheumatology (ACR) Annual Meeting...
Can we reverse diabetes? – Abarceo Pharma aims to develop the...
World Diabetes Day on November 14 raised awareness of diabetes as one of the greatest public health challenges of our time, along with the...
Curasight announces brain cancer as initial target for uTREAT
Brain cancer will be the first indication for Curasight’s uTREAT therapy. The company’s decision to choose aggressive brain cancer for a fast single indications...